5-HT receptor

Last updated
The 5-HT1B receptor as an example of a metabotropic serotonin receptor. Its crystallographic structure in ribbon representation 4IAR.png
The 5-HT1B receptor as an example of a metabotropic serotonin receptor. Its crystallographic structure in ribbon representation

5-HT receptors, 5-hydroxytryptamine receptors, or serotonin receptors, are a group of G protein-coupled receptor and ligand-gated ion channels found in the central and peripheral nervous systems. [1] [2] [3] They mediate both excitatory and inhibitory neurotransmission. The serotonin (i.e., 5-hydroxytryptamine, hence "5-HT") receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand.

Contents

The serotonin receptors modulate the release of many neurotransmitters, including glutamate, GABA, dopamine, epinephrine / norepinephrine, and acetylcholine, as well as many hormones, including oxytocin, prolactin, vasopressin, cortisol, corticotropin, and substance P, among others. Serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation. They are the target of a variety of pharmaceutical and recreational drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens. [4]

Serotonin receptors are found in almost all animals and are even known to regulate longevity and behavioral aging in the primitive nematode, Caenorhabditis elegans . [5] [6]

Classification

5-hydroxytryptamine receptors or 5-HT receptors, or serotonin receptors are found in the central and peripheral nervous systems. [1] [2] They can be divided into 7 families of G protein-coupled receptors which activate an intracellular second messenger cascade to produce an excitatory or inhibitory response. The exception to this is the 5-HT3 receptor which is a ligand-gated ion channel. In 2014, a novel 5-HT receptor was isolated from the small white butterfly, Pieris rapae, and named pr5-HT8. It does not occur in mammals and shares relatively low similarity to the known 5-HT receptor classes. [7]

Families

FamilyTypeMechanismPotential
5-HT1 Gi/Go-protein coupled.Decreasing cellular levels of cAMP.Inhibitory
5-HT2 Gq/G11-protein coupled.Increasing cellular levels of IP3 and DAG.Excitatory
5-HT3 Ligand-gated Na+ and K+ cation channel. Depolarizing plasma membrane.Excitatory
5-HT4 Gs-protein coupled.Increasing cellular levels of cAMP.Excitatory
5-HT5 Gi/Go-protein coupled. [8] Decreasing cellular levels of cAMP.Inhibitory
5-HT6 Gs-protein coupled.Increasing cellular levels of cAMP.Excitatory
5-HT7 Gs-protein coupled.Increasing cellular levels of cAMP.Excitatory

Subtypes

The 7 general serotonin receptor classes include a total of 14 known serotonin receptors. [9] The 15th receptor 5-HT1P has been distinguished on the basis of functional and radioligand binding studies, its existence has never been definitely affirmed or refuted. [10] [11] The specific types have been characterized as follows: [12] [13] [14]

Information on serotonin receptors (human isoforms if nothing else is stated)
ReceptorFirst cloned – PDB entries Gene(s)DistributionFunction Agonists Antagonists Uses of drugs that act on this receptor
Blood vessels CNS GI Tract Platelets PNS Smooth Muscle
5-HT1A 1987 –
  • 7e2x
  • 7e2y
  • 7e2z

7E2Y 5-HT1A receptor serotonin.png

YesYesNoNoNoNo

Selective (for 5-HT1A over other 5-HT receptors)

Nonselective

5-HT1B 1992 –
  • 6g79
YesYesNoNoNoNo
5-HT1D 1991 –
  • 7e32

7E32 5-HT1D receptor.png

YesYesNoNoNoNo
5-HT1E 1992 –
  • 7e33

7E33 5-HT1E receptor.png

YesYesNoNoNoNo
  • None known
5-HT1F 1993 –
  • 7exd

7exd 5-HT1F receptor.png

NoYesNoNoNoNo
  • Migraine
  • None known
5-HT1PNot clonedNoNoYesNoNoNo
  • None known
5-HT2A 1988YesYesYesYesYesYes
  • Addiction (potentially modulating) [54]
  • Anxiety [55]
  • Appetite
  • Cognition
  • Imagination
  • Learning
  • Memory
  • Mood
  • Perception
  • Sexual Behavior [56]
  • Sleep [57]
  • Thermoregulation [58]
  • Vasoconstriction [59]
5-HT2B 1992YesYesYesYesYesYes
5-HT2C 1988YesYesYesYesYesYes
5-HT3 1993NoYesYesNoYesNo
  • Addiction
  • Anxiety
  • Emesis
  • GI Motility [77]
  • Learning [78]
  • Memory [78]
  • Nausea
5-HT4 1995NoYesYesNoYesNo
5-HT5A 1994 NoYesNoNoNoNo
  • None thus far
5-HT5B 1993NoNoNoNoNoNo

Functions in rodents,
pseudogene in humans

  • None thus far
5-HT6 1993NoYesNoNoNoNo
5-HT7 1993YesYesYesNoNoNo

Note that there is no 5-HT1C receptor since, after the receptor was cloned and further characterized, it was found to have more in common with the 5-HT2 family of receptors and was redesignated as the 5-HT2C receptor. [107]

Very nonselective agonists of 5-HT receptor subtypes include ergotamine (an antimigraine), which activates 5-HT1A, 5-HT1D, 5-HT1B, D2 and norepinephrine receptors. [38] LSD (a psychedelic) is a 5-HT1A, 5-HT2A, 5-HT2C, 5-HT5A and 5-HT6 agonist. [38]

Expression patterns

The genes coding for serotonin receptors are expressed across the mammalian brain. Genes coding for different receptors types follow different developmental curves. Specifically, there is a developmental increase of HTR5A expression in several subregions of the human cortex, paralleled by a decreased expression of HTR1A from the embryonic period to the post-natal one. [108]

5-HT1-like

A number of receptors were classed as "5-HT1-like" - by 1998 it was being argued that, since these receptors were "a heterogeneous population of 5-HT1B, 5-HT1D and 5-HT7" receptors the classification was redundant. [109]

Related Research Articles

5-HT<sub>2A</sub> receptor Subtype of serotonin receptor

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor, but has several intracellular locations.

<span class="mw-page-title-main">Serotonin receptor agonist</span> Neurotransmission-modulating substance

A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin, a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.

The 5-HT1 receptors are a subfamily of the 5-HT serotonin receptors that bind to the endogenous neurotransmitter serotonin (also known as 5-hydroxytryptamine, or 5-HT). The 5-HT1 subfamily consists of five G protein-coupled receptors (GPCRs) that share 40% to 63% overall sequence homology, including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F. Receptors of the 5-HT1 type, specifically, the 5-HT1A and 5-HT1D receptor subtypes, are present on the cell bodies. Receptors of the 5-HT1 type, specifically, the 5-HT1B and 5-HT1D receptor subtypes, are also present on the nerve terminals. These receptors are broadly distributed throughout the brain and are recognized to play a significant part in regulating synaptic levels of 5-HT.

5-HT<sub>1A</sub> receptor Serotonin receptor protein distributed in the cerebrum and raphe nucleus

The serotonin 1A receptor is a subtype of serotonin receptors, or 5-HT receptors, that binds serotonin, also known as 5-HT, a neurotransmitter. 5-HT1A is expressed in the brain, spleen, and neonatal kidney. It is a G protein-coupled receptor (GPCR), coupled to the Gi protein, and its activation in the brain mediates hyperpolarization and reduction of firing rate of the postsynaptic neuron. In humans, the serotonin 1A receptor is encoded by the HTR1A gene.

5-HT<sub>1B</sub> receptor Mammalian protein found in Homo sapiens

5-hydroxytryptamine receptor 1B also known as the 5-HT1B receptor is a protein that in humans is encoded by the HTR1B gene. The 5-HT1B receptor is a 5-HT receptor subtype.

<span class="mw-page-title-main">8-OH-DPAT</span> Chemical compound

8-OH-DPAT is a research chemical of the aminotetralin chemical class which was developed in the 1980s and has been widely used to study the function of the 5-HT1A receptor. It was one of the first major 5-HT1A receptor full agonists to have been discovered.

5-HT<sub>2B</sub> receptor Mammalian protein found in Homo sapiens

5-Hydroxytryptamine receptor 2B (5-HT2B) also known as serotonin receptor 2B is a protein that in humans is encoded by the HTR2B gene. 5-HT2B is a member of the 5-HT2 receptor family that binds the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Like all 5-HT2 receptors, the 5-HT2B receptor is Gq/G11-protein coupled, leading to downstream activation of phospholipase C.

5-HT<sub>5A</sub> receptor Protein-coding gene in the species Homo sapiens

5-Hydroxytryptamine (serotonin) receptor 5A, also known as HTR5A, is a protein that in humans is encoded by the HTR5A gene. Agonists and antagonists for 5-HT receptors, as well as serotonin uptake inhibitors, present promnesic (memory-promoting) and/or anti-amnesic effects under different conditions, and 5-HT receptors are also associated with neural changes.

5-HT<sub>6</sub> receptor Protein-coding gene in the species Homo sapiens

The 5HT6 receptor is a subtype of 5HT receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5HT). It is a G protein-coupled receptor (GPCR) that is coupled to Gs and mediates excitatory neurotransmission. HTR6 denotes the human gene encoding for the receptor.

5-HT<sub>7</sub> receptor Protein-coding gene in the species Homo sapiens

The 5-HT7 receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). The 5-HT7 receptor is coupled to Gs (stimulates the production of the intracellular signaling molecule cAMP) and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels. This receptor has been a drug development target for the treatment of several clinical disorders. The 5-HT7 receptor is encoded by the HTR7 gene, which in humans is transcribed into 3 different splice variants.

<span class="mw-page-title-main">WAY-100635</span> Chemical compound

WAY-100635 is a piperazine drug and research chemical widely used in scientific studies. It was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor. It is sometimes referred to as a silent antagonist at the former receptor. It is closely related to WAY-100135.

<span class="mw-page-title-main">SB-242084</span> Chemical compound

SB-242084 is a psychoactive drug and research chemical which acts as a selective antagonist for the 5HT2C receptor. It has anxiolytic effects, and enhances dopamine signalling in the limbic system, as well as having complex effects on the dopamine release produced by cocaine, increasing it in some brain regions but reducing it in others. It has been shown to increase the effectiveness of the selective serotonin reuptake inhibitor (SSRI) class of antidepressants, and may also reduce their side effects. In animal studies, SB-242084 produced stimulant-type activity and reinforcing effects, somewhat similar to but much weaker than cocaine or amphetamines.

<span class="mw-page-title-main">5-Carboxamidotryptamine</span> Chemical compound

5-Carboxamidotryptamine (5-CT) is a tryptamine derivative closely related to the neurotransmitter serotonin.

<span class="mw-page-title-main">CP-94253</span> Potent and selective serotonin 5-HT1B receptor agonist

CP-94253 is a drug which acts as a potent and selective serotonin 5-HT1B receptor agonist, with approximately 25× and 40× selectivity over the closely related 5-HT1D and 5-HT1A receptors. It has a range of behavioral effects, based on animal testing. The effects include the following: promoting wakefulness by increasing dopamine release in the brain; reducing food intake and promoting satiety; enhancing the reinforcing effects of cocaine; and possible antidepressant effects. A recent study found that "Regardless of sex, CP94253 decreased cocaine intake after abstinence and during resumption of SA [self-administration] and decreased cue reactivity" suggesting that agonism of the inhibitory 5-HT2B receptors may diminish the cognitive reward of cocaine usage and increased use of the drug without a period of abstinence may be a product of test subjects trying to achieve a previously rewarding experience through larger dosages of cocaine.

<span class="mw-page-title-main">Osemozotan</span> Pharmaceutical drug

Osemozotan (MKC-242) is a selective 5-HT1A receptor agonist with some functional selectivity, acting as a full agonist at presynaptic and a partial agonist at postsynaptic 5-HT1A receptors. 5-HT1A receptor stimulation influences the release of various neurotransmitters including serotonin, dopamine, norepinephrine, and acetylcholine. 5-HT1A receptors are inhibitory G protein-coupled receptor.

<span class="mw-page-title-main">Pruvanserin</span> Chemical compound

Pruvanserin is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.

<span class="mw-page-title-main">Naphthylpiperazine</span> Chemical compound

1-(1-Naphthyl)piperazine (1-NP) is a drug which is a phenylpiperazine derivative. It acts as a non-selective, mixed serotonergic agent, exerting partial agonism at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptors, while antagonizing the 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has also been shown to possess high affinity for the 5-HT3, 5-HT5A, 5-HT6, and 5-HT7 receptors, and may bind to 5-HT4 and the SERT as well. In animals it produces effects including hyperphagia, hyperactivity, and anxiolysis, of which are all likely mediated predominantly or fully by blockade of the 5-HT2C receptor.

<span class="mw-page-title-main">SB-206553</span> Chemical compound

SB-206553 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors. It has anxiolytic properties in animal studies and interacts with a range of other drugs. It has also been shown to act as a positive allosteric modulator of α7 nicotinic acetylcholine receptors. Modified derivatives of SB-206553 have been used to probe the structure of the 5-HT2B receptor.

<span class="mw-page-title-main">SB-243213</span> Chemical compound

SB-243213 is a research chemical which acts as a selective inverse agonist for the 5HT2C receptor and has anxiolytic effects. It has better than 100x selectivity for 5-HT2C over all other receptor subtypes tested, and a longer duration of action compared to older 5-HT2C antagonist ligands.

<span class="mw-page-title-main">Hypidone</span> Investigational antidepressant drug

Hypidone (developmental code name YL-0919) is an investigational serotonergic antidepressant which is under development for the treatment of major depressive disorder. It acts as a serotonin reuptake inhibitor, 5-HT1A receptor partial agonist, and 5-HT6 receptor full agonist. It is used as the hydrochloride salt. As of January 2021, hypidone is in phase 2 clinical trials for major depressive disorder.

References

  1. 1 2 Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. (June 1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews. 46 (2): 157–203. PMID   7938165.
  2. 1 2 Frazer A, Hensler JG (1999). "Chapter 13: Serotonin Receptors". In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds.). Basic Neurochemistry: MolecularCellular, and Medical Aspects. Philadelphia: Lippincott-Raven. pp. 263–292. ISBN   978-0-397-51820-3.
  3. ↑ Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, et al. (January 2017). "A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System". The Journal of Neuroscience. 37 (1): 120–128. doi:10.1523/jneurosci.2830-16.2016. PMC   5214625 . PMID   28053035.
  4. ↑ Nichols DE, Nichols CD (May 2008). "Serotonin receptors". Chemical Reviews. 108 (5): 1614–1641. doi:10.1021/cr078224o. PMID   18476671.
  5. ↑ Murakami H, Murakami S (August 2007). "Serotonin receptors antagonistically modulate Caenorhabditis elegans longevity". Aging Cell. 6 (4): 483–488. doi: 10.1111/j.1474-9726.2007.00303.x . PMID   17559503. S2CID   8345654.
  6. ↑ Murakami H, Bessinger K, Hellmann J, Murakami S (July 2008). "Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans". Neurobiology of Aging. 29 (7): 1093–1100. doi:10.1016/j.neurobiolaging.2007.01.013. PMID   17336425. S2CID   37671716.
  7. ↑ Qi YX, Xia RY, Wu YS, Stanley D, Huang J, Ye GY (December 2014). "Larvae of the small white butterfly, Pieris rapae, express a novel serotonin receptor". Journal of Neurochemistry. 131 (6): 767–777. doi:10.1111/jnc.12940. PMID   25187179. S2CID   21621635.
  8. ↑ Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (November 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309. doi:10.1016/S0014-2999(98)00744-4. PMID   9865521.
  9. ↑ Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 4. ISBN   9780071481274. Similarly, little is known about which of serotonin's 14 known receptors must be activated to achieve an antidepressant response.
  10. ↑ Brady ST (2012). Basic Neurochemistry - Principles of Molecular, Cellular and Medical Neurobiology (8th ed.). Waltham, MA: USA: Elsevier. pp. 320–321. ISBN   978-0-12-374947-5.
  11. 1 2 3 4 Mitchell NA, Pepperell E, Ociepka S, Brown JD, Witherington J, Tuladhar B, et al. (July 2009). "5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon". Neurogastroenterology and Motility. 21 (7): 760–e48. doi:10.1111/j.1365-2982.2009.01275.x. PMID   19309442. S2CID   9532359.
  12. ↑ Glennon RA, Dukat M, Westkaemper RB (2000-01-01). "Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
  13. ↑ "5-Hydroxytryptamine Receptors". IUPHAR Receptor Database. International Union of Basic and Clinical Pharmacology. Retrieved 2008-04-11.
  14. ↑ Wesołowska A (2002). "In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors" (PDF). Polish Journal of Pharmacology. 54 (4): 327–341. PMID   12523486.
  15. ↑ Tomkins DM, Higgins GA, Sellers EM (June 1994). "Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1–2): 173–179. doi:10.1007/BF02244769. PMID   7862892. S2CID   38012716.
  16. ↑ Müller CP, Carey RJ, Huston JP, De Souza Silva MA (February 2007). "Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors". Progress in Neurobiology. 81 (3): 133–178. doi:10.1016/j.pneurobio.2007.01.001. PMID   17316955. S2CID   42788995.
  17. ↑ Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (February 2005). "Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects". Brain Research. 1034 (1–2): 162–171. doi:10.1016/j.brainres.2004.12.012. PMID   15713268. S2CID   28356741.
  18. 1 2 de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–139. doi:10.1016/j.ejphar.2005.09.065. PMID   16310183.
  19. ↑ Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (September 1998). "Increased anxiety of mice lacking the serotonin1A receptor". Proceedings of the National Academy of Sciences of the United States of America. 95 (18): 10734–10739. Bibcode:1998PNAS...9510734P. doi: 10.1073/pnas.95.18.10734 . PMC   27964 . PMID   9724773.
  20. ↑ Ebenezer IS, Arkle MJ, Tite RM (May 2007). "8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in Experimental and Clinical Pharmacology. 29 (4): 269–272. doi:10.1358/mf.2007.29.4.1075362. PMID   17609739.
  21. 1 2 Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–223. doi:10.1016/0014-2999(88)90651-6. PMID   2842163.
  22. 1 2 Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–76. doi:10.1016/j.autneu.2008.06.004. PMID   18667366. S2CID   20878941.
  23. ↑ Nalivaiko E, Ootsuka Y, Blessing WW (August 2005). "Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 289 (2): R596–R604. doi:10.1152/ajpregu.00845.2004. PMID   15802554. S2CID   17426759.
  24. 1 2 Lucot JB (February 1994). "Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1–2): 53–60. doi:10.1016/0014-2999(94)90756-0. PMID   8013549.
  25. ↑ Winstanley CA, Theobald DE, Dalley JW, Robbins TW (April 2005). "Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders". Neuropsychopharmacology. 30 (4): 669–682. doi: 10.1038/sj.npp.1300610 . PMID   15688093.
  26. ↑ Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, et al. (December 2008). "The role of 5-HT(1A) receptors in learning and memory". Behavioural Brain Research. 195 (1): 54–77. doi:10.1016/j.bbr.2008.02.023. PMID   18394726. S2CID   140205386.
  27. ↑ Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. (February 2003). "Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory". The American Journal of Psychiatry. 160 (2): 334–340. doi:10.1176/appi.ajp.160.2.334. PMID   12562581.
  28. ↑ Kennett GA, Dourish CT, Curzon G (February 1987). "Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression". European Journal of Pharmacology. 134 (3): 265–274. doi:10.1016/0014-2999(87)90357-8. PMID   2883013.
  29. ↑ Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC (April 2003). "Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain". Pharmacology. 67 (4): 182–194. doi:10.1159/000068404. PMID   12595749. S2CID   25882138.
  30. 1 2 Millan MJ, Perrin-Monneyron S (March 1997). "Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 321 (3): R11–R13. doi:10.1016/S0014-2999(97)00050-2. PMID   9085055.
  31. ↑ Prow MR, Martin KF, Heal DJ (December 1996). "8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation". European Journal of Pharmacology. 317 (1): 21–28. doi:10.1016/S0014-2999(96)00693-0. PMID   8982715.
  32. 1 2 Meyer LC, Fuller A, Mitchell D (February 2006). "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (2): R405–R413. doi:10.1152/ajpregu.00440.2005. PMID   16166206. S2CID   224414.
  33. 1 2 Popova NK, Amstislavskaya TG (July 2002). "Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice". Psychoneuroendocrinology. 27 (5): 609–618. doi:10.1016/S0306-4530(01)00097-X. PMID   11965359. S2CID   25269315.
  34. ↑ Monti JM, Jantos H (September 1992). "Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat". Journal of Sleep Research. 1 (3): 169–175. doi: 10.1111/j.1365-2869.1992.tb00033.x . PMID   10607047.
  35. ↑ Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")". Neuroscience. 146 (2): 509–514. doi:10.1016/j.neuroscience.2007.02.032. PMID   17383105. S2CID   15617471.
  36. ↑ Gudelsky GA, Koenig JI, Meltzer HY (December 1986). "Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors". Neuropharmacology. 25 (12): 1307–1313. doi:10.1016/0028-3908(86)90101-2. PMID   2951611. S2CID   2547042.
  37. ↑ Ootsuka Y, Blessing WW (February 2006). "Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits". Brain Research. 1073–1074: 252–261. doi:10.1016/j.brainres.2005.12.031. PMID   16455061. S2CID   23178233.
  38. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Pharmacology Corner > Serotonin (5-HT): receptors, agonists and antagonists By Flavio Guzmán, M.D. on 9/08/09
  39. 1 2 3 4 5 "BRINTELLIX (vortioxetine) tablets for oral use. Full Prescribing Information, Section 12.2 (Pharmacodynamics)." Takeda Pharmaceuticals America Inc. and Lundbeck, 2013. Revised September 2013. Archived 2019-09-18 at the Wayback Machine
  40. ↑ Saxena PR, Lawang A (October 1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives Internationales de Pharmacodynamie et de Therapie. 277 (2): 235–252. PMID   2933009.
  41. ↑ Cao BJ, Rodgers RJ (October 1998). "Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice". Psychopharmacology. 139 (3): 185–194. doi:10.1007/s002130050703. PMID   9784072. S2CID   9466299.
  42. ↑ Harrison AA, Parsons LH, Koob GF, Markou A (January 1999). "RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist". Psychopharmacology. 141 (3): 242–250. doi:10.1007/s002130050831. PMID   10027505. S2CID   19974789.
  43. ↑ Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E (February 2005). "The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action". The Journal of Pharmacy and Pharmacology. 57 (2): 253–257. doi:10.1211/0022357055399. PMID   15720791. S2CID   20743875.
  44. ↑ Lin D, Parsons LH (April 2002). "Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze". Pharmacology, Biochemistry, and Behavior. 71 (4): 581–587. doi:10.1016/S0091-3057(01)00712-2. PMID   11888549. S2CID   21610537.
  45. 1 2 Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E (December 2004). "Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression". Behavioural Pharmacology. 15 (8): 523–534. doi:10.1097/00008877-200412000-00001. PMID   15577451. S2CID   6940756.
  46. 1 2 Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO (June 2008). "Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission". Neuropharmacology. 54 (7): 1041–1050. doi:10.1016/j.neuropharm.2008.02.007. hdl:10616/40922. PMID   18394658. S2CID   207223573.
  47. 1 2 McCreary AC, Bankson MG, Cunningham KA (September 1999). "Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors". The Journal of Pharmacology and Experimental Therapeutics. 290 (3): 965–973. PMID   10454466.
  48. ↑ Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J (May 2005). "Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study". European Neuropsychopharmacology. 15 (3): 279–282. doi:10.1016/j.euroneuro.2004.12.002. PMID   15820416. S2CID   8382188.
  49. ↑ Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB (May 1996). "5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex". Neuroscience Letters. 209 (3): 210–214. doi:10.1016/0304-3940(96)12637-9. PMID   8736648. S2CID   27376524.
  50. ↑ Najjar SA, Hung LY, Margolis KG (June 2023). "Serotonergic Control of Gastrointestinal Development, Motility, and Inflammation". Comprehensive Physiology. 13 (3): 4851–4868. doi:10.1002/cphy.c220024. ISBN   9780470650714. PMC   10373054 . PMID   37358510.
  51. ↑ Branchek TA, Mawe GM, Gershon MD (July 1988). "Characterization and localization of a peripheral neural 5-hydroxytryptamine receptor subtype (5-HT1P) with a selective agonist, 3H-5-hydroxyindalpine". The Journal of Neuroscience. 8 (7): 2582–2595. doi:10.1523/JNEUROSCI.08-07-02582.1988. PMC   6569501 . PMID   3249244.
  52. ↑ Mawe GM, Branchek TA, Gershon MD (December 1986). "Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists". Proceedings of the National Academy of Sciences of the United States of America. 83 (24): 9799–9803. Bibcode:1986PNAS...83.9799M. doi: 10.1073/pnas.83.24.9799 . PMC   387229 . PMID   3467338.
  53. ↑ Annaházi, Anita; Berger, Thomas Erwin; Demir, Ihsan Ekin; Zeller, Florian; Müller, Michael; Anneser, Markus; Skerra, Arne; Michel, Klaus; Schemann, Michael (April 2022). "Metabotropic 5-HT receptor-mediated effects in the human submucous plexus". Neurogastroenterology & Motility. 34 (10): e14380. doi: 10.1111/nmo.14380 . ISSN   1350-1925. PMID   35438222. S2CID   248241342.
  54. 1 2 Bubar MJ, Cunningham KA (2006). "Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence". Current Topics in Medicinal Chemistry. 6 (18): 1971–1985. doi:10.2174/156802606778522131. PMID   17017968.
  55. ↑ Schreiber R, Melon C, De Vry J (February 1998). "The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test". Psychopharmacology. 135 (4): 383–391. doi:10.1007/s002130050526. PMID   9539263. S2CID   22677071.
  56. 1 2 Popova NK, Amstislavskaya TG (July 2002). "5-HT2A and 5-HT2C serotonin receptors differentially modulate mouse sexual arousal and the hypothalamo-pituitary-testicular response to the presence of a female". Neuroendocrinology. 76 (1): 28–34. doi:10.1159/000063681. PMID   12097814. S2CID   42319246.
  57. 1 2 Popa D, Léna C, Fabre V, Prenat C, Gingrich J, Escourrou P, et al. (December 2005). "Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors". The Journal of Neuroscience. 25 (49): 11231–11238. doi:10.1523/JNEUROSCI.1724-05.2005. PMC   6725907 . PMID   16339018.
  58. 1 2 Mazzola-Pomietto P, Aulakh CS, Tolliver T, Murphy DL (March 1997). "Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists". Psychopharmacology. 130 (2): 144–151. doi:10.1007/s002130050222. PMID   9106912. S2CID   22432569.
  59. ↑ Blessing WW, Seaman B (2003). "5-hydroxytryptamine(2A) receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats". Neuroscience. 117 (4): 939–948. doi:10.1016/S0306-4522(02)00810-2. PMID   12654345. S2CID   53251590.
  60. 1 2 3 McCall RB, Franklin SR, Hyslop DK, Knauer CS, Chio CL, Haber CL, Fitzgerald LW (2001). PNU-22394, a 5-HT2C receptor agonist, reduced feeding in rodents and produces weight loss in humans (Online). Society for Neuroscience. Vol. 27. Presentation Number 309.2. San Diego, CA: Society for Neuroscience Abstracts. p. TT-45. Retrieved 18 July 2014.
  61. 1 2 3 Garfield AS, Heisler LK (January 2009). "Pharmacological targeting of the serotonergic system for the treatment of obesity". The Journal of Physiology. 587 (1): 49–60. doi:10.1113/jphysiol.2008.164152. PMC   2670022 . PMID   19029184.
  62. 1 2 3 Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–1227. CiteSeerX   10.1.1.691.154 . doi:10.1021/jm301656h. PMID   23301527.
  63. ↑ Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP (April 1996). "Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety". British Journal of Pharmacology. 117 (7): 1443–1448. doi:10.1111/j.1476-5381.1996.tb15304.x. PMC   1909458 . PMID   8730737.
  64. ↑ Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC (1997). "Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat". Neuropharmacology. 36 (4–5): 601–608. doi:10.1016/S0028-3908(97)00042-7. PMID   9225285. S2CID   41471226.
  65. ↑ Kennett GA, Trail B, Bright F (December 1998). "Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated". Neuropharmacology. 37 (12): 1603–1610. doi:10.1016/S0028-3908(98)00115-4. PMID   9886683. S2CID   7310462.
  66. ↑ Kennett GA, Ainsworth K, Trail B, Blackburn TP (February 1997). "BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats". Neuropharmacology. 36 (2): 233–239. doi:10.1016/S0028-3908(96)00171-2. PMID   9144661. S2CID   23583570.
  67. ↑ Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, et al. (March 2002). "5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro". British Journal of Pharmacology. 135 (5): 1144–1151. doi:10.1038/sj.bjp.0704571. PMC   1573235 . PMID   11877320.
  68. ↑ Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al. (1997). "SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist". Neuropharmacology. 36 (4–5): 609–620. doi:10.1016/S0028-3908(97)00038-5. PMID   9225286. S2CID   23032157.
  69. 1 2 Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–458. doi:10.1007/s00213-004-1962-z. PMID   15289999. S2CID   20866665.
  70. 1 2 Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, et al. (September 2008). "S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models". Psychopharmacology. 199 (4): 549–568. doi:10.1007/s00213-008-1177-9. PMID   18523738. S2CID   25063495.
  71. ↑ Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, et al. (May 2009). "Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin". Biological Psychiatry. 65 (9): 748–759. doi:10.1016/j.biopsych.2008.10.031. PMID   19058784. S2CID   22053616.
  72. ↑ Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (April 1997). "5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists". European Journal of Pharmacology. 325 (1): 9–12. doi:10.1016/S0014-2999(97)89962-1. PMID   9151932.
  73. ↑ Stancampiano R, Melis MR, Argiolas A (August 1994). "Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission". European Journal of Pharmacology. 261 (1–2): 149–155. doi:10.1016/0014-2999(94)90313-1. PMID   8001637.
  74. ↑ Frank MG, Stryker MP, Tecott LH (November 2002). "Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor". Neuropsychopharmacology. 27 (5): 869–873. doi:10.1016/S0893-133X(02)00353-6. PMC   2452994 . PMID   12431861.
  75. ↑ Villalobos CA, Bull P, Sáez P, Cassels BK, Huidobro-Toro JP (April 2004). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes". British Journal of Pharmacology. 141 (7): 1167–1174. doi:10.1038/sj.bjp.0705722. PMC   1574890 . PMID   15006903.
  76. ↑ Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN   978-0-443-07145-4. Page 187
  77. ↑ Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, et al. (May 2005). "Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors". Gastroenterology. 128 (5): 1317–1326. doi: 10.1053/j.gastro.2005.02.005 . PMID   15887114.
  78. 1 2 Pitsikas N, Brambilla A, Borsini F (January 1994). "Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task". Pharmacology, Biochemistry, and Behavior. 47 (1): 95–99. doi:10.1016/0091-3057(94)90116-3. PMID   8115433. S2CID   21800364.
  79. 1 2 Smriga M, Torii K (December 2003). "L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats". Proceedings of the National Academy of Sciences of the United States of America. 100 (26): 15370–15375. Bibcode:2003PNAS..10015370S. doi: 10.1073/pnas.2436556100 . PMC   307574 . PMID   14676321.
  80. ↑ Kennett GA, Bright F, Trail B, Blackburn TP, Sanger GJ (1997). "Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats". Neuropharmacology. 36 (4–5): 707–712. doi:10.1016/S0028-3908(97)00037-3. PMID   9225297. S2CID   40341646.
  81. ↑ Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, et al. (October 2007). "Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens". Proceedings of the National Academy of Sciences of the United States of America. 104 (41): 16335–16340. Bibcode:2007PNAS..10416335J. doi: 10.1073/pnas.0701471104 . PMC   2042207 . PMID   17913892.
  82. ↑ Compan V, Charnay Y, Dusticier N, Daszuta A, Hen R, Bockaert J (2004). "[Feeding disorders in 5-HT4 receptor knockout mice]". Journal de la Société de Biologie. 198 (1): 37–49. doi:10.1051/jbio/2004198010037. PMID   15146954. S2CID   90408378.
  83. 1 2 Meneses A, Hong E (March 1997). "Effects of 5-HT4 receptor agonists and antagonists in learning". Pharmacology, Biochemistry, and Behavior. 56 (3): 347–351. doi:10.1016/S0091-3057(96)00224-9. PMID   9077568. S2CID   11866740.
  84. 1 2 Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM (1997). "The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation". Neuropharmacology. 36 (4–5): 689–696. doi:10.1016/S0028-3908(97)00055-5. PMID   9225295. S2CID   46510811.
  85. ↑ Galeotti N, Ghelardini C, Bartolini A (September 1998). "Role of 5-HT4 receptors in the mouse passive avoidance test". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1115–1121. PMID   9732367.
  86. ↑ Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. (September 2007). "Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action". Neuron. 55 (5): 712–725. doi: 10.1016/j.neuron.2007.07.041 . PMID   17785179. S2CID   14558104.
  87. ↑ Duman RS (September 2007). "A silver bullet for the treatment of depression?". Neuron. 55 (5): 679–681. doi: 10.1016/j.neuron.2007.08.011 . PMID   17785173.
  88. ↑ Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW (July 2003). "5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia". Science. 301 (5630): 226–229. Bibcode:2003Sci...301..226M. doi:10.1126/science.1084674. PMID   12855812. S2CID   13641423.
  89. ↑ Nelson DL (February 2004). "5-HT5 receptors". Current Drug Targets. CNS and Neurological Disorders. 3 (1): 53–58. doi:10.2174/1568007043482606. PMID   14965244.
  90. 1 2 Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (August 2005). "Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro". Brain Research. Molecular Brain Research. 138 (2): 191–197. doi:10.1016/j.molbrainres.2005.04.009. PMC   5805132 . PMID   15921820.
  91. 1 2 3 Zhang S, Chen H, Zhang C, Yang Y, Popov P, Liu J, et al. (July 2022). "Inactive and active state structures template selective tools for the human 5-HT5A receptor". Nature Structural & Molecular Biology. 29 (7): 677–687. doi:10.1038/s41594-022-00796-6. PMC   9299520 . PMID   35835867.
  92. ↑ Wesołowska A (February 2008). "The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors". European Journal of Pharmacology. 580 (3): 355–360. doi:10.1016/j.ejphar.2007.11.022. PMID   18096153.
  93. 1 2 Wesołowska A, Nikiforuk A (April 2007). "Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression". Neuropharmacology. 52 (5): 1274–1283. doi:10.1016/j.neuropharm.2007.01.007. PMID   17320917. S2CID   22664564.
  94. ↑ Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, et al. (December 2006). "SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models". European Journal of Pharmacology. 553 (1–3): 109–119. doi:10.1016/j.ejphar.2006.09.049. PMID   17069795.
  95. 1 2 Perez-García G, Meneses A (July 2005). "Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task". Pharmacology, Biochemistry, and Behavior. 81 (3): 673–682. doi:10.1016/j.pbb.2005.05.005. PMID   15964617. S2CID   19789219.
  96. ↑ Wesołowska A, Nikiforuk A (March 2008). "The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats". European Journal of Pharmacology. 582 (1–3): 88–93. doi:10.1016/j.ejphar.2007.12.013. PMID   18234190.
  97. ↑ Alcalde E, Mesquida N, López-Pérez S, Frigola J, Mercè R (Feb 2009). "Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists". Journal of Medicinal Chemistry. 52 (3): 675–87. doi:10.1021/jm8009469. PMID   19159187.
  98. ↑ "Target Schizophrenia - Possible future developments". The Association of the British Pharmaceutical Industry. Archived from the original on 2008-06-12. Retrieved 2008-04-11.
  99. 1 2 3 Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (November 2005). "5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern". Biological Psychiatry. 58 (10): 831–837. doi:10.1016/j.biopsych.2005.05.012. PMID   16018977. S2CID   10998014.
  100. 1 2 Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (September 2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–586. doi:10.1016/j.neuropharm.2006.04.017. PMID   16828124. S2CID   39928418.
  101. ↑ Gasbarri A, Cifariello A, Pompili A, Meneses A (December 2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–170. doi:10.1016/j.bbr.2007.12.020. PMID   18308404. S2CID   12910296.
  102. ↑ Liy-Salmeron G, Meneses A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–974. doi:10.1002/hipo.20459. PMID   18570192. S2CID   20937527.
  103. 1 2 Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, et al. (May 2007). "Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents". The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 690–698. doi:10.1124/jpet.107.119404. PMID   17314195. S2CID   14579645.
  104. ↑ Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, et al. (June 2003). "SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats". British Journal of Pharmacology. 139 (4): 705–714. doi:10.1038/sj.bjp.0705290. PMC   1573887 . PMID   12812993.
  105. ↑ León-Ponte, Matilde; Ahern, Gerard P.; O'Connell, Peta J. (2007-04-15). "Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor". Blood. 109 (8): 3139–3146. doi:10.1182/blood-2006-10-052787. ISSN   0006-4971. PMC   1852236 . PMID   17158224.
  106. ↑ Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf
  107. ↑ "HTR2C 5-hydroxytryptamine receptor 2C [ Homo sapiens (human) ]". NCBI. 19 Mar 2017. Retrieved 26 Mar 2017.
  108. ↑ Bar-Shira O, Maor R, Chechik G (December 2015). "Gene Expression Switching of Receptor Subunits in Human Brain Development". PLOS Computational Biology. 11 (12): e1004559. Bibcode:2015PLSCB..11E4559B. doi: 10.1371/journal.pcbi.1004559 . PMC   4670163 . PMID   26636753.
  109. ↑ Saxena PR, De Vries P, Villalón CM (August 1998). "5-HT1-like receptors: a time to bid goodbye". Trends in Pharmacological Sciences. 19 (8): 311–316. doi:10.1016/S0165-6147(98)01228-0. PMID   9745358.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.